pharmaphorum

UCB bags FDA okay for first drug to treat rare disease TK2d

Transmission electron microscope image of a thin section cut through an area of mammalian lung tissue. The high magnification image shows two mitochondria. People living with thymidine kinase 2 ...
Investing

FDA approves first treatment for rare genetic disease TK2d

The worldwide prevalence of TK2d is estimated at 1.64 cases per million people. UCB expects KYGEVVI to be commercially available in the U.S. in the first quarter of 2026. The treatment had previously ...
pharmaphorum

UCB brings first therapy for rare disease TK2d to EU

Patients in the EU with rare disease thymidine kinase 2 deficiency (TK2d) have their first approved therapy, UCB's Kygevvi, after the European Commission cleared the drug "under exceptional ...
manilatimes

FDA Approves KYGEVVI® (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare and ...

New York, Nov. 03, 2025 (GLOBE NEWSWIRE) -- New York, Monday, November 3, 2025 - The Muscular Dystrophy Association (MDA) marks another milestone today in our legacy of progress with the FDA approval ...
GEN

FDA Approves First Treatment for Rare Thymidine Kinase 2 Deficiency

Thymidine kinase 2 deficiency (TK2d) is an ultra-rare (1.64 cases per 1,000,000 people) often fatal, genetic mitochondrial disease characterized by progressive and severe muscle weakness. Those ...
MM&M

The long road to yes: How years of persistence finally led to a treatment for ultra-rare TK2d deficiency

Genetically precise, but therapeutically untouchable. Thymidine kinase 2 deficiency (TK2d) has hid in a clinical blind spot for most of the time since scientists first identified it in 2001. Families ...
PharmiWeb

U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

“The approval of doxecitine and doxribtimine represents a pivotal moment for the TK2d community who previously had no FDA-approved treatment options for this rare genetic mitochondrial disease beyond ...
Investing

FDA approves first treatment for rare genetic disease TK2d

ATLANTA - The U.S. Food and Drug Administration has approved KYGEVVI (doxecitine and doxribtimine) as the first treatment for thymidine kinase 2 deficiency (TK2d), UCB announced Monday. The ...
Mena FN

FDA Approves KYGEVVI® (Doxecitine And Doxribtimine), The First And Only Treatment For Adults And Children Living With Thymidine Kinase 2 Deficiency (Tk2d), A Rare And ...

(MENAFN- GlobeNewsWire - Nasdaq) This novel therapy offers the first FDA-approved option to address the root cause of this ultra-rare condition, which causes progressive muscle weakness impairing ...
Finanznachrichten

UCB: U.S. FDA approves KYGEVVI (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

Approved indication: KYGEVVI ® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients ...
Finanznachrichten

U.S. FDA approves KYGEVVI (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

The KYGEVVI approval is supported by safety and efficacy data from one Phase 2 clinical study, two retrospective chart review studies, and an expanded access use program*. 1,8,9,10,11 These studies ...